NPS Pharmaceuticals names new chief medical officer
Dr Garceau replaces Alan Harris who is leaving NPS for personal reasons but remains as a scientific advisor to the company. Dr Garceau joins NPS from Sanofi-Aventis, where
Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.
New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development, Morgenthaler Ventures, Novartis BioVentures and
According to the company, HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, has demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug